One step forward, two steps back for prescription apps
Ironwood signs up with the leading prescription app developer, but Pear is not to everyone’s taste.
Another robot deal for J&J shows up lack of Verb results
Johnson & Johnson is going in hard on robotics, but its first big move here has still not paid off.
Through Gilead, Galapagos secures an independent future
For $5bn up front Gilead has effectively gained access to the Belgian company’s pipeline, in a deal that will tie the US biotech to Galapagos for many years to come.
Astrazeneca asset swap kickstarts Innate's independence
Innate swaps its lead candidate for Astra’s Lumoxiti in a bid to become a rare cancer player.
Promotion deal is huge boost for Exact – but Pfizer must deliver
Pfizer is to push Exact’s cancer test in a deal that could “permanently alter the trajectory of Cologuard”.
Merck & Co hedges its checkpoint bet with Lenvima
Eisai deal to help Merck expand checkpoint inhibitor franchise.
Takeda forges another neuroscience deal as Abbvie dips a toe
Takeda's appetite for risk in early stage neuroscience could make it one to watch.
